Viibryd (VI-brid, vilazodone), a new "dual-acting" antidepressant

July 2011

You'll see orders for Viibryd (VI-brid, vilazodone), a new "dual-acting" antidepressant.

Viibryd works in two ways to boost levels of serotonin...a chemical in the brain involved in improving mood.

The company hoped Viibryd would work better than an "SSRI." But it doesn't...and may cause more stomach side effects, like diarrhea.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

Corticosteroids handle the methylprednisolone drug shortage
Practice using NDC numbers to identify meds
Statins stronger warnings and dose limits for simvastatin
Restless Legs new option for restless legs syndrome, Horizant (hor-i-zant, gabapentin enacarbil)
Diabetes Meds confusing the news about Avandia and Actos
Antidepressants Viibryd (VI-brid, vilazodone), a new "dual-acting" antidepressant
Aspirin whether the new Bayer Advanced Aspirin works "faster" for pain than regular aspirin
COPD Daliresp (DA-li-resp, roflumilast), a new oral tab for people with severe chronic obstructive pulmonary disease (COPD)
Thyroid Disorders preventing mishaps with levothyroxine (Synthroid, Levoxyl, Levothroid, etc) Rxs
Antibiotics the new oral antibiotic, Dificid (DIF-eh-sid, fidaxomicin), for treating Clostridium difficile diarrhea
Antidepressants whether it's okay to combine certain antidepressants
Asthma Singulair is "as good as" inhaled steroids (Advair, Flovent, etc) for preventing asthma attacks
Diabetes how to manage diabetes during fasting